News
COPENHAGEN/LONDON (Reuters) - Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and ...
Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.
Analysis-Novo Nordisk Should Look to the US for Its ... CEO of Novo Nordisk Lars Fruergaard Jorgensen is seen during the 6th ... who campaigned on a promise to boost domestic manufacturing, ...
Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.
Catalent is an attractive buyout target for Novo Holdings, which owns 77% of the voting shares in Novo Nordisk. The deal could boost availability of the drugs because Catalent is the main supplier ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results